Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record.

Estrogens and anti‐estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates

Ho, Shuk‐Mei·2004·Journal of Cellular Biochemistry

Abstract

Despite the historical use of estrogens in the treatment of prostate cancer (PCa) little is known about their direct biological effects on the prostate, their role in carcinogenesis, and what mechanisms mediate their therapeutic effects on PCa. It is now known that estrogens alone, or in synergism with an androgen, are potent inducers of aberrant growth and neoplastic transformation in the prostate. The mechanisms of estrogen carcinogenicity could be mediated via induction of unscheduled cell proliferation or through metabolic activation of estrogens to genotoxic metabolites. Age‐related changes and race‐/ethnic‐based differences in circulating or locally formed estrogens may explain differential PCa risk among different populations. Loss of expression of estrogen receptor (ER)‐β expression during prostate carcinogenesis and prevention of estrogen‐mediated oxidative damage could be exploited in future PCa prevention strategies. Re‐expression of ER‐β in metastatic PCa cells raises the possibility of using ER‐β‐specific ligands in triggering cell death in these malignant cells. A variety of new estrogenic/anti‐estrogenic/selective estrogen receptor modulator (SERM)‐like compounds, including 2‐methoxyestradiol, genistein, resveratrol, licochalcone, Raloxifene, ICI 182,780, and estramustine are being evaluated for their potential in the next generation of PCa therapies. Increasing numbers of patients self‐medicate with herbal formulations such as PC‐SPES. Some of these compounds are selective ER‐β ligands, while most of them have minimal interaction with ER‐α. Although many may inhibit testosterone production by blockade of the hypothalamal–pituitary–testis axis, the most effective agents also exhibit direct cytostatic, cytotoxic, or apoptotic action on PCa cells. Some of them are potent in interfering with tubulin polymerization, blocking angiogenesis and cell motility, suppressing DNA synthesis, and inhibiting specific kinase activities. Further discovery of other compounds with potent apoptotic activities but minimal estrogen action should promote development of a new generation of effective PCa preventive or treatment regimens with few or no side‐effects due to estrogenicity. Further advancement of our knowledge of the role of estrogens in prostate carcinogenesis through metabolic activation of estrogens and/or ER‐mediated pathways will certainly result in better preventive or therapeutic modalities for PCa. © 2003 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcb.10759

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 196

Metadata

Authors
Ho, S.
Venue
Journal of Cellular Biochemistry
Publisher
Wiley
Published
2003-12-11
Volume
91
Issue
3
Pages
491-503
ISSN
  • 0730-2312 (ISSN-L)
  • 1097-4644
OpenAlex
W1986749657
Cited by
196
References
0
FWCI
10.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estrogens and anti‐estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. https://app.cochat.ai/papers/10.1002/jcb.10759
The paper
Ho, S. (2004). Estrogens and anti‐estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.10759

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.